희소 바이오마커 검체 수집 및 안정화 시장 규모, 점유율, 동향 분석 보고서 : 바이오마커별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

Rare Biomarkers Specimen Collection And Stabilization Market Growth & Trends:

The global rare biomarkers specimen collection and stabilization market size is expected to reach USD 92.39 billion by 2030, expanding at a CAGR of 14.4% from 2025 to 2030, according to a new report by Grand View Research, Inc. Expanding potential applications of circulating rare biomarkers has created lucrative opportunities for the technology developers that are engaged in the introduction of products to support the effective and rapid collection and stabilization of these rare biomarkers specimen. Furthermore, the emergence of liquid biopsy for cancer screening, diagnosis, prognosis, and treatment monitoring has significantly enhanced the competition and capabilities in the market for rare biomarkers specimen collection and stabilization, thereby aiding in revenue growth.

Given the potential of circulating biomarkers, both as high-value therapy delivery systems and as potential diagnostics, researchers are adopting more sensitive, rapid, and flexible analytical tools. Key players are developing novel technologies and products for collection and stabilization of these rare biomarkers specimen to expand research possibilities. Despite a substantial number of advantages, there are still challenges to overcome their clinical application.

Although most of the isolation methods are highly specific and sensitive, thus far, there is lack of sufficient evidence on the use and efficacy of the products in clinical samples. This hampers the clinical use of rare biomarkers specimen because differences in analytical sensitivity between these methods play a very crucial role. However, an increase in studies on the clinical utility of these rare biomarkers specimen is anticipated to effectively address the clinical implementation-related challenges.

Rare Biomarkers Specimen Collection And Stabilizations Market Report Highlights:

• The circulating cell-free DNA (ccfDNA) segment accounted for the largest share of the market at 36.0% in 2024.
• The research segment captured the highest share of 74.1% in 2024. The dominance of the rare biomarker segment is largely due to the growing number of research studies focused on their implementation.
• The diagnostics segment expected to expand at the CAGR of 15.0% by 2030. While rare biomarkers such as Circulating Cell-Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), and exosomes have primarily been used in research settings, they are increasingly being explored for diagnostic applications.
• North America rare biomarkers specimen collection and stabilization industry dominated and accounted for a 52.1% share in 2024.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Biomarker
  • 1.2.2. End Use
  • 1.2.3. Regional scope
  • 1.2.4. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Biomarker outlook
  • 2.2.2. End use outlook
  • 2.2.3. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Rare Biomarkers Specimen Collection and Stabilization Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Rising Demand for Precision Medicine
    • 3.2.1.2. Advancements in Liquid Biopsy Technologies
    • 3.2.1.3. Increasing Prevalence of Chronic and Genetic Diseases
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High Costs
    • 3.2.2.2. Lack of Standardization
• 3.3. Rare Biomarkers Specimen Collection and Stabilization Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Rare Biomarkers Specimen Collection and Stabilization Market: Biomarker Estimates & Trend Analysis

• 4.1. Biomarker Market Share, 2024 & 2030
• 4.2. Segment Dashboard
• 4.3. Global Rare Biomarkers Specimen Collection and Stabilization Market by Biomarker Outlook
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.4.1. Circulating Cell Free DNA (ccfDNA)
    • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
  • 4.4.2. Circulating Tumor Cells (CTCs)
    • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD million)
  • 4.4.3. Exosomes/Extracellular Vesicles
    • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD million)
    • 4.4.3.2. By Product
      • 4.4.3.2.1. Isolation Kits & Reagents
        • 4.4.3.2.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
      • 4.4.3.2.2. Blood Collection Tubes
        • 4.4.3.2.2.1. Market estimates and forecasts 2018 to 2030 (USD million)
      • 4.4.3.2.3. Systems
        • 4.4.3.2.3.1. Market estimates and forecasts 2018 to 2030 (USD million)
    • 4.4.3.3. By Specimen Type
      • 4.4.3.3.1. Serum/Plasma
        • 4.4.3.3.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
      • 4.4.3.3.2. Others
        • 4.4.3.3.2.1. Market estimates and forecasts 2018 to 2030 (USD million)
    • 4.4.3.4. By Nucleic Acid & Other Biomolecules
      • 4.4.3.4.1. RNA
        • 4.4.3.4.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
      • 4.4.3.4.2. DNA
        • 4.4.3.4.2.1. Market estimates and forecasts 2018 to 2030 (USD million)
      • 4.4.3.4.3. Others
        • 4.4.3.4.3.1. Market estimates and forecasts 2018 to 2030 (USD million)
    • 4.4.3.5. By Application
      • 4.4.3.5.1. NIPT
        • 4.4.3.5.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
      • 4.4.3.5.2. Oncology
      • 4.4.3.5.3. Market estimates and forecasts 2018 to 2030 (USD million)
        • 4.4.3.5.3.1. Research
          • 4.4.3.5.3.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
        • 4.4.3.5.3.2. Diagnostics
          • 4.4.3.5.3.2.1. Market estimates and forecasts 2018 to 2030 (USD million)
          • 4.4.3.5.3.2.2. Screening
    • 4.4.3.5.3.2.2.1. Market estimates and forecasts 2018 to 2030 (USD million)
      • 4.4.3.5.3.2.3. Treatment Monitoring
    • 4.4.3.5.3.2.3.1. Market estimates and forecasts 2018 to 2030 (USD million)
      • 4.4.3.5.4. Transcriptomics
        • 4.4.3.5.4.1. Market estimates and forecasts 2018 to 2030 (USD million)
      • 4.4.3.5.5. Pharmacogenomics
        • 4.4.3.5.5.1. Market estimates and forecasts 2018 to 2030 (USD million)
      • 4.4.3.5.6. Transplant Rejection
        • 4.4.3.5.6.1. Market estimates and forecasts 2018 to 2030 (USD million)
      • 4.4.3.5.7. Population Screening
        • 4.4.3.5.7.1. Market estimates and forecasts 2018 to 2030 (USD million)
      • 4.4.3.5.8. Cardiovascular Diseases
        • 4.4.3.5.8.1. Market estimates and forecasts 2018 to 2030 (USD million)
      • 4.4.3.5.9. Other Applications
        • 4.4.3.5.9.1. Market estimates and forecasts 2018 to 2030 (USD million)
  • 4.4.4. Circulating Cell Free RNA (ccfRNA) / miRNA
    • 4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD million)
    • 4.4.4.2. By Product
      • 4.4.4.2.1. Isolation Kits & Reagents
        • 4.4.4.2.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
      • 4.4.4.2.2. Blood Collection Tubes
        • 4.4.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD million)
    • 4.4.4.3. By Application
      • 4.4.4.3.1. NIPT
        • 4.4.4.3.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
      • 4.4.4.3.2. Oncology
        • 4.4.4.3.2.1. Market estimates and forecasts 2018 to 2030 (USD million)
        • 4.4.4.3.2.2. Research
          • 4.4.4.3.2.2.1. Market estimates and forecasts 2018 to 2030 (USD million)
        • 4.4.4.3.2.3. Diagnostics
          • 4.4.4.3.2.3.1. Market estimates and forecasts 2018 to 2030 (USD million)
      • 4.4.4.3.3. Transcriptomics
        • 4.4.4.3.3.1. Market estimates and forecasts 2018 to 2030 (USD million)
      • 4.4.4.3.4. Pharmacogenomics
        • 4.4.4.3.4.1. Market estimates and forecasts 2018 to 2030 (USD million)
      • 4.4.4.3.5. Transplant Rejection
        • 4.4.4.3.5.1. Market estimates and forecasts 2018 to 2030 (USD million)
      • 4.4.4.3.6. Population Screening
        • 4.4.4.3.6.1. Market estimates and forecasts 2018 to 2030 (USD million)
      • 4.4.4.3.7. Cardiovascular Diseases
        • 4.4.4.3.7.1. Market estimates and forecasts 2018 to 2030 (USD million)
      • 4.4.4.3.8. Other Applications
        • 4.4.4.3.8.1. Market estimates and forecasts 2018 to 2030 (USD million)

Chapter 5. Rare Biomarkers Specimen Collection and Stabilization Market: End Use Estimates & Trend Analysis

• 5.1. End Use Market Share, 2024 & 2030
• 5.2. Segment Dashboard
• 5.3. Global Rare Biomarkers Specimen Collection and Stabilization Market by End Use Outlook
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.4.1. Research
    • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD million)
    • 5.4.1.2. Research Labs/CROs
      • 5.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.1.3. Academic Institutes
      • 5.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.2. Diagnostics
    • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2.2. Laboratories
      • 5.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2.3. Hospitals
      • 5.4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2.4. Prenatal clinics
      • 5.4.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Rare Biomarkers Specimen Collection and Stabilization Market: Regional Estimates & Trend Analysis

• 6.1. Regional Market Share Analysis, 2024 & 2030
• 6.2. Regional Market Dashboard
• 6.3. Global Regional Market Snapshot
• 6.4. Market Size & Forecasts Trend Analysis, 2018 to 2030:
• 6.5. North America
  • 6.5.1. U.S.
    • 6.5.1.1. Key country dynamics
    • 6.5.1.2. Regulatory framework/ reimbursement structure
    • 6.5.1.3. Competitive scenario
    • 6.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.2. Canada
    • 6.5.2.1. Key country dynamics
    • 6.5.2.2. Regulatory framework/ reimbursement structure
    • 6.5.2.3. Competitive scenario
    • 6.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.3. Mexico
    • 6.5.3.1. Key country dynamics
    • 6.5.3.2. Regulatory framework/ reimbursement structure
    • 6.5.3.3. Competitive scenario
    • 6.5.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million
• 6.6. Europe
  • 6.6.1. UK
    • 6.6.1.1. Key country dynamics
    • 6.6.1.2. Regulatory framework/ reimbursement structure
    • 6.6.1.3. Competitive scenario
    • 6.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.2. Germany
    • 6.6.2.1. Key country dynamics
    • 6.6.2.2. Regulatory framework/ reimbursement structure
    • 6.6.2.3. Competitive scenario
    • 6.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.3. France
    • 6.6.3.1. Key country dynamics
    • 6.6.3.2. Regulatory framework/ reimbursement structure
    • 6.6.3.3. Competitive scenario
    • 6.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.4. Italy
    • 6.6.4.1. Key country dynamics
    • 6.6.4.2. Regulatory framework/ reimbursement structure
    • 6.6.4.3. Competitive scenario
    • 6.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.5. Spain
    • 6.6.5.1. Key country dynamics
    • 6.6.5.2. Regulatory framework/ reimbursement structure
    • 6.6.5.3. Competitive scenario
    • 6.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.6. Norway
    • 6.6.6.1. Key country dynamics
    • 6.6.6.2. Regulatory framework/ reimbursement structure
    • 6.6.6.3. Competitive scenario
    • 6.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.7. Sweden
    • 6.6.7.1. Key country dynamics
    • 6.6.7.2. Regulatory framework/ reimbursement structure
    • 6.6.7.3. Competitive scenario
    • 6.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.8. Denmark
    • 6.6.8.1. Key country dynamics
    • 6.6.8.2. Regulatory framework/ reimbursement structure
    • 6.6.8.3. Competitive scenario
    • 6.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 6.7. Asia Pacific
  • 6.7.1. Japan
    • 6.7.1.1. Key country dynamics
    • 6.7.1.2. Regulatory framework/ reimbursement structure
    • 6.7.1.3. Competitive scenario
    • 6.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.2. China
    • 6.7.2.1. Key country dynamics
    • 6.7.2.2. Regulatory framework/ reimbursement structure
    • 6.7.2.3. Competitive scenario
    • 6.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.3. India
    • 6.7.3.1. Key country dynamics
    • 6.7.3.2. Regulatory framework/ reimbursement structure
    • 6.7.3.3. Competitive scenario
    • 6.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.4. Australia
    • 6.7.4.1. Key country dynamics
    • 6.7.4.2. Regulatory framework/ reimbursement structure
    • 6.7.4.3. Competitive scenario
    • 6.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.5. South Korea
    • 6.7.5.1. Key country dynamics
    • 6.7.5.2. Regulatory framework/ reimbursement structure
    • 6.7.5.3. Competitive scenario
    • 6.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.6. Thailand
    • 6.7.6.1. Key country dynamics
    • 6.7.6.2. Regulatory framework/ reimbursement structure
    • 6.7.6.3. Competitive scenario
    • 6.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 6.8. Latin America
  • 6.8.1. Brazil
    • 6.8.1.1. Key country dynamics
    • 6.8.1.2. Regulatory framework/ reimbursement structure
    • 6.8.1.3. Competitive scenario
    • 6.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.8.1.5. )
  • 6.8.2. Argentina
    • 6.8.2.1. Key country dynamics
    • 6.8.2.2. Regulatory framework/ reimbursement structure
    • 6.8.2.3. Competitive scenario
    • 6.8.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 6.9. MEA
  • 6.9.1. South Africa
    • 6.9.1.1. Key country dynamics
    • 6.9.1.2. Regulatory framework/ reimbursement structure
    • 6.9.1.3. Competitive scenario
    • 6.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.9.2. Saudi Arabia
    • 6.9.2.1. Key country dynamics
    • 6.9.2.2. Regulatory framework/ reimbursement structure
    • 6.9.2.3. Competitive scenario
    • 6.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.9.3. UAE
    • 6.9.3.1. Key country dynamics
    • 6.9.3.2. Regulatory framework/ reimbursement structure
    • 6.9.3.3. Competitive scenario
    • 6.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.9.4. Kuwait
    • 6.9.4.1. Key country dynamics
    • 6.9.4.2. Regulatory framework/ reimbursement structure
    • 6.9.4.3. Competitive scenario
    • 6.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis, By Key Market Participants
• 7.2. Company/Competition Categorization
• 7.3. Vendor Landscape
  • 7.3.1. Key company market share analysis, 2024
  • 7.3.2. QIAGEN
    • 7.3.2.1. Company overview
    • 7.3.2.2. Financial performance
    • 7.3.2.3. Product benchmarking
    • 7.3.2.4. Strategic initiatives
  • 7.3.3. Charles River Laboratories
    • 7.3.3.1. Company overview
    • 7.3.3.2. Financial performance
    • 7.3.3.3. Product benchmarking
    • 7.3.3.4. Strategic initiatives
  • 7.3.4. F. Hoffmann-La Roche Ltd
    • 7.3.4.1. Company overview
    • 7.3.4.2. Financial performance
    • 7.3.4.3. Product benchmarking
    • 7.3.4.4. Strategic initiatives
  • 7.3.5. Terumo Medical Corp
    • 7.3.5.1. Company overview
    • 7.3.5.2. Financial performance
    • 7.3.5.3. Product benchmarking
    • 7.3.5.4. Strategic initiatives
  • 7.3.6. Thermofischer Scientific Inc
    • 7.3.6.1. Company overview
    • 7.3.6.2. Financial performance
    • 7.3.6.3. Product benchmarking
    • 7.3.6.4. Strategic initiatives
  • 7.3.7. Eurofins Scientific
    • 7.3.7.1. Company overview
    • 7.3.7.2. Financial performance
    • 7.3.7.3. Product benchmarking
    • 7.3.7.4. Strategic initiatives
  • 7.3.8. PerkinElmer Inc
    • 7.3.8.1. Company overview
    • 7.3.8.2. Financial performance
    • 7.3.8.3. Product benchmarking
    • 7.3.8.4. Strategic initiatives
  • 7.3.9. Bio-Rad Laboratories, Inc
    • 7.3.9.1. Company overview
    • 7.3.9.2. Financial performance
    • 7.3.9.3. Product benchmarking
    • 7.3.9.4. Strategic initiatives
  • 7.3.10. Agilent Technologies, Inc
    • 7.3.10.1. Company overview
    • 7.3.10.2. Financial performance
    • 7.3.10.3. Product benchmarking
    • 7.3.10.4. Strategic initiatives
  • 7.3.11. Merck KGaA
    • 7.3.11.1. Company overview
    • 7.3.11.2. Financial performance
    • 7.3.11.3. Product benchmarking
    • 7.3.11.4. Strategic initiatives
  • 7.3.12. Siemens Healthcare GmbH
    • 7.3.12.1. Company overview
    • 7.3.12.2. Financial performance
    • 7.3.12.3. Product benchmarking
    • 7.3.12.4. Strategic initiatives